Fennec Pharmaceuticals announced acceptance of four abstracts evaluating PEDMARK for presentation or publication at the 2026 ASCO Annual Meeting, highlighting clinical interest in cisplatin-induced hearing loss prevention.
Key takeaways
Four abstracts on PEDMARK accepted at 2026 ASCO Annual Meeting (May 29-June 2, Chicago, IL).
Two poster presentations: Japanese STS-J01 study (June 1) and Phase 1 GCT trial (May 31).
Two abstract-only publications on real-world feasibility in young adults and audiometric outcomes in head/neck cancer.
PEDMARK FDA-approved to reduce ototoxicity risk in pediatric patients with localized solid tumors.
Full abstracts available on ASCO website May 21, 2026.